A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.
The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.
advertisement
In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds
Next article： Alkermes shareholders re
Next article： Alkermes shareholders re
